Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|July 1, 2007
- Volume 0 0
Update on Investigational Alzheimer's Drug
Author(s)Susan Farley
Advertisement
Voyager Pharmaceutical Corp recently informed its shareholders of preliminary results from a trial of an investigational drug to treat Alzheimer's disease (AD). The researchers studying the drug, Memryte, observed positive effects among women but not among men.
The findings have prompted Voyager to focus on developing the drug to treat AD specifically for women.
Articles in this issue
about 19 years ago
pharmacy TECHNOLOGY newsabout 19 years ago
pharmacy TECHNOLOGY productsabout 19 years ago
health-systems PRODUCT newsabout 19 years ago
generic times product newsabout 19 years ago
can you READ these Rxs?about 19 years ago
A closer look at new FDA actionsabout 19 years ago
can you READ these Rxs?about 19 years ago
compounding HOTLINEabout 19 years ago
Is There Science in Quality?about 19 years ago
Vaccines: Are You Protected?Advertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5